{"classes":[{"categories":[{"measurements":[{"comment":"Median overall survival was not met before the data cutoff point because more than half of the participants were still alive","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"The median overall survival as measured from the start of treatment until the time of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction (Cycles 1-9): Lenalidomide orally, days 1-21. Bortezomib injection, days 1, 8, 15, 22. Dexamethasone orally, days 1, 2, 8, 9, 15, 16, 22, 23 (for subjects 75 years of age or younger), or Dexamethasone orally days 1, 8, 15, 22 (for subjects greater than 75 years of age)\n\nConsolidation (cycles 10-15): Lenalidomide po daily (1-21). Bortezomib sc on days 1, 15\n\nLenalidomide\n\nBortezomib\n\nDexamethasone","id":"OG000","title":"Treatment Arm"}],"paramType":"MEDIAN","populationDescription":"Median overall survival was not met before the end of follow-up/ data cutoff point because more than half of the participants were still alive.","reportingStatus":"POSTED","timeFrame":"From the start of treatment until death or until 5 years after the time of disease progression","title":"Median Overall Survival","type":"SECONDARY","unitOfMeasure":"years"}